Key points are not available for this paper at this time.
Complement inhibition is the standard of care in PNH and atypical hemolytic uremic syndrome (aHUS). Crovalimab (crova), a C5 inhibitor, enables rapid, complete, and sustained C5 inhibition with subcutaneous self-administration in patients (pts) with PNH who are complement inhibitor naive or switching to crova. Crova has non-inferior efficacy vs eculizumab (ecu) and a safety profile consistent with that of other C5 inhibitors. Here we evaluate kidney function in the Phase 3 pts.
Soldati et al. (2024) studied this question.